High-flow nasal cannula failure: can clinical outcomes determine early interruption?

Area of Science:

• Pediatrics
• Respiratory Medicine
• Critical Care

Background:

• Bronchiolitis is a common viral respiratory infection in infants.
• High-flow nasal cannula (HFNC) therapy is increasingly used for moderate to severe bronchiolitis.
• Determining optimal duration for HFNC therapy is crucial for effective patient management.

Purpose of the Study:

• To assess the clinical outcome evolution in pediatric patients with bronchiolitis treated with HFNC.
• To establish criteria for discontinuing HFNC and escalating ventilatory support based on clinical response.

Main Methods:

• Observational retrospective study of infants with bronchiolitis receiving HFNC.
• Patients categorized into Success and Failure groups based on HFNC therapy outcome.
• Clinical variables (respiratory rate, oxygen saturation) monitored at 30 minutes and 6 hours post-initiation.

Main Results:

• Of 83 children, 18 (21.7%) experienced HFNC therapy failure.
• Successful HFNC therapy showed significant improvements in respiratory rate and oxygen saturation within 30 minutes (p<0.001).
• Significant differences in respiratory rate and oxygen saturation were observed between Success and Failure groups at 6 hours (p<0.01).

Conclusions:

• Absence of clinical improvement within 30 minutes to 6 hours suggests HFNC therapy failure in bronchiolitis.
• Escalation to alternative ventilatory support should be considered if no improvement is noted within this 6-hour window.